# Atacicept in Multiple Sclerosis Extension Study, Phase II

> **NCT00853762** · PHASE2 · TERMINATED · sponsor: **EMD Serono** · enrollment: 74 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Atacicept 25 mg
- **DRUG:** Atacicept 75 mg
- **DRUG:** Atacicept 150 mg
- **DRUG:** Atacicept 150 mg

## Key facts

- **NCT ID:** NCT00853762
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2009-09
- **Final completion:** 2011-02
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]
- **Last updated:** 2017-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853762, "Atacicept in Multiple Sclerosis Extension Study, Phase II". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00853762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*